Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.

Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA.

Mol Cancer Ther. 2016 Dec;15(12):3015-3027. Epub 2016 Oct 7.

PMID:
27765849
2.

Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks.

Simmons AJ, Scurrah CR, McKinley ET, Herring CA, Irish JM, Washington MK, Coffey RJ, Lau KS.

Sci Signal. 2016 Oct 11;9(449):rs11.

3.

Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T.

World J Gastroenterol. 2016 Jul 7;22(25):5668-77. doi: 10.3748/wjg.v22.i25.5668. Review.

4.

BRAF-Directed Therapy in Metastatic Colorectal Cancer.

Korphaisarn K, Kopetz S.

Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189. Review.

5.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.

PMID:
27312529
6.

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations.

Ahronian LG, Corcoran RB.

Mol Cell Oncol. 2015 May 21;3(1):e1048405. doi: 10.1080/23723556.2015.1048405. eCollection 2016 Jan.

7.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE.

Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.

PMID:
27222538
8.

Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Sharma V, Young L, Cavadas M, Owen K; Reproducibility Project: Cancer Biology.

Elife. 2016 Mar 21;5. pii: e11414. doi: 10.7554/eLife.11414.

9.

Colorectal clinical trials: what is on the horizon?

Ahn DH, Goldberg RM.

Future Oncol. 2016 Feb;12(4):525-31. doi: 10.2217/fon.15.327. Epub 2016 Jan 18. Review.

10.

New therapeutic strategies for BRAF mutant colorectal cancers.

Corcoran RB.

J Gastrointest Oncol. 2015 Dec;6(6):650-9. doi: 10.3978/j.issn.2078-6891.2015.076. Review.

11.

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.

12.

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

Wu PK, Park JI.

Semin Oncol. 2015 Dec;42(6):849-62. doi: 10.1053/j.seminoncol.2015.09.023. Epub 2015 Sep 24. Review.

13.

BRAF Mutation in Colorectal Cancer: An Update.

Barras D.

Biomark Cancer. 2015 Sep 6;7(Suppl 1):9-12. doi: 10.4137/BIC.S25248. eCollection 2015. Review.

14.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.

J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.

15.

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT.

Mol Cancer Ther. 2015 Dec;14(12):2773-81. doi: 10.1158/1535-7163.MCT-15-0243. Epub 2015 Sep 17.

16.

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets.

Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A, Paliogiannis P, Ascierto PA, Cossu A.

Front Oncol. 2015 Aug 10;5:183. doi: 10.3389/fonc.2015.00183. eCollection 2015. Review.

17.

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.

Morkel M, Riemer P, Bläker H, Sers C.

Oncotarget. 2015 Aug 28;6(25):20785-800. Review.

18.

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Amin AD, Rajan SS, Liang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH.

Cancer Res. 2015 Jul 15;75(14):2916-27. doi: 10.1158/0008-5472.CAN-14-3437. Epub 2015 May 27.

19.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA.

Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.

20.

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.

Tang HC, Chen YC.

Int J Nanomedicine. 2015 Apr 23;10:3131-46. doi: 10.2147/IJN.S80150. eCollection 2015.

Supplemental Content

Support Center